The potential presence of a placebo instead of the drug itself in a portion of the product has prompted the recall of Estarylla tablets by Sandoz. The drug, an oral contraceptive, is being recalled on the heels of a user reporting that, within the row of actual tablets, there was a placebo. The company notes that the potential for unintended pregnancy is relatively low due to the placebo’s differing appearance from regular pills. No one has reported experiencing any type of adversity at this time. Nevertheless, Sandoz has went ahead with the recall of the affected lot, which will have a Lot number of LF01213A and an expiration date of February of next year. Users are being advised to speak with a doctor if they fear a lack of quality assurance.
For more about the recall, click here.